The Ontario Government announced the Funding Accelerated for Specific Treatments (FAST) program to fast-track access for breakthrough cancer drugs.

Ontario is consulting with stakeholders in expanding the scope of practice for a range of healthcare professionals including optometrists, psychologists, physiotherapists and others.

RAMQ announced their changes to Patient d’exception bringing in stricter requirements rolled out in three phases between July 2 to December 11, 2025.

Following the review of 54 feedback submissions, the PMPRB went ahead with new Guidelnes.

President Trump’s latest Executive Order is to bring most-favored-nation prescription drug pricing to the US.

A US Presidential Order was issued April 15 to lower drug costs. One section of the Executive Order is to help US States import drugs from “other jurisdictions”.

All provinces and territories have now signed bilateral agreements with the federal government as per the National Strategy for Drugs for Rare Diseases.

Today, Ontario signed the National Strategy for Drugs for Rare Diseases (DRD) agreement with the federal government for $535 million in funding.

As promised, the PMPRB did indeed publish their draft Guidelines before the end of 2024. Given the posting date of Dec 19, the 90-day consultation period will end March 19, 2025.

IMC welcomes Canada's Premiers' announcement of a pilot project to reduce the time from Canadian Drug Agency recommendation to public listing for essential cancer drugs. Up to 9 months will be cut to the time for listing.